CARA - Cara Therapeutics, Inc.
IEX Last Trade
0.421
0.007 1.663%
Share volume: 900
Last Updated: Thu 26 Dec 2024 04:30:02 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.82%
PREVIOUS CLOSE
CHG
CHG%
$0.41
0.01
1.69%
Fundamental analysis
37%
Profitability
25%
Dept financing
11%
Liquidity
75%
Performance
45%
Performance
5 Days
9.70%
1 Month
52.20%
3 Months
67.00%
6 Months
40.48%
1 Year
-30.67%
2 Year
-95.50%
Key data
Stock price
$0.42
DAY RANGE
$0.41 - $0.43
52 WEEK RANGE
$0.26 - $1.15
52 WEEK CHANGE
-$29.78
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Christopher Posner
Region: US
Website: caratherapeutics.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: caratherapeutics.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Cara Therapeutics, Inc. focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe Pruritus associated with chronic kidney disease (CKD)
Recent news